Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant

Inclusion Criteria

• Must be at least 18 years old or the legal age of consent.
• Able to provide informed consent and follow study requirements.
• Diagnosed with newly diagnosed multiple myeloma needing treatment.
• Must have measurable disease based on specific lab tests.
• Not eligible for high-dose chemotherapy with stem cell transplant due to age (70 or older), other health conditions, or personal choice.
• Good overall health with an ECOG performance status of 0 to 2.
• Adequate organ function based on lab tests.
• Male participants must agree to use contraception and avoid donating sperm during and after treatment.
• Female participants must not be pregnant or breastfeeding and must use effective contraception if of childbearing potential.

Exclusion Criteria

• Have certain other blood disorders or types of cancer.
• Have had previous treatment for multiple myeloma.
• Have cancer affecting the brain or nervous system.
• Have had major surgery recently or not fully recovered from surgery.
• Have serious medical or psychiatric conditions that could interfere with the study.
• Have active liver or bile duct disease, except for certain stable conditions.
• Have other cancers unless stable for at least 2 years.
• Have significant heart problems or recent heart events.
• Have HIV unless well-controlled with treatment.
• Have hepatitis C unless successfully treated.
• Have hepatitis B unless specific criteria are met.
• Have current eye disease except for mild conditions.
• Cannot tolerate antiviral or blood clot prevention medications.
• Have allergies to study drugs or components.
• Have had plasmapheresis recently.
• Have received a live vaccine recently.